万达生物制药宣布，其候选药物Imsidolimab用于治疗泛发性脓疱型银屑病（GPP）的孤儿药资格申请，已获得欧洲药品管理局（EMA）人用药品委员会（CHMP）的积极意见。
孤儿药资格旨在鼓励针对罕见疾病的药物开发。获得EMA的积极意见是Imsidolimab在欧洲监管路径上的一个重要进展，为其后续的上市申请奠定了基础。这一进展有望为GPP患者带来新的治疗希望。
万达生物制药宣布，其候选药物Imsidolimab用于治疗泛发性脓疱型银屑病（GPP）的孤儿药资格申请，已获得欧洲药品管理局（EMA）人用药品委员会（CHMP）的积极意见。
孤儿药资格旨在鼓励针对罕见疾病的药物开发。获得EMA的积极意见是Imsidolimab在欧洲监管路径上的一个重要进展，为其后续的上市申请奠定了基础。这一进展有望为GPP患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.